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Abstract
Background: Ultrasonography allows for non-invasive examination of the liver and spleen and can further our
understanding of schistosomiasis morbidity.
Methodology/Principal Findings: We followed 578 people in Southwest China for up to five years. Participants were tested
for Schistosoma japonicum infection in stool and seven standard measures of the liver and spleen were obtained using
ultrasound to evaluate the relationship between schistosomiasis infection and ultrasound-detectable pathology, and the
impact of targeted treatment on morbidity. Parenchymal fibrosis, a network pattern of the liver unique to S. japonicum, was
associated with infection at the time of ultrasound (OR 1.40, 95% CI: 1.03–1.90) and infection intensity (test for trend,
p=0.002), adjusting for age, sex and year, and more strongly associated with prior infection status and intensity (adjusted
OR 1.84, 95% CI: 1.30–2.60; test for trend: p,0.001 respectively), despite prompt treatment of infections. While declines in
parenchymal fibrosis over time were statistically significant, only 28% of individuals with severe parenchymal fibrosis
(grades 2 or 3) at enrollment reversed to normal or grade 1 within five years. Other liver abnormalities were less consistently
associated with S. japonicum infection.
Conclusions/Significance: Parenchymal fibrosis is an appropriate measure of S. japonicum morbidity and can document
reductions in disease following control efforts. Other ultrasound measures may have limited epidemiological value in
regions with similar infection levels. Because severe fibrosis may not reverse quickly following treatment, efforts to reduce
exposure to S. japonicum should be considered in combination with treatment to prevent schistosomiasis morbidity.
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Introduction
Schistosomiasis causes morbidity in the human host through the
schistosome egg, which triggers inflammation and fibrosis that can
lead to anemia, impaired growth and in severe cases, gastrointes-
tinal bleeding and death [1–4]. The major intestinal schistosomes,
Schistosoma japonicum, found in Asia, and S. mansoni, found in Africa,
the Americas and the Middle East, mature, mate and lay eggs in
the portal and mesenteric blood vessels. Eggs are transported to
the liver where they are encapsulated and the granulomas that
form induce an inflammatory cascade that includes the deposition
of collagen and extracellular matrix proteins, a normal liver repair
process that can lead to fibrosis when fibrogenesis exceeds the
replacement of scar tissue with healthy cells [5,6]. The immune
regulation of this process is currently being explored [7].
Approximately 700,000 people are infected with S. japonicum in
China [8]. As in other parts of the world, schistosomiasis control
efforts have focused primarily on the distribution of the
antischistosomal drug, praziquantel [9,10]. However the success
of such efforts hinges on the ability to reduce not only
schistosomiasis infections, but also morbidity. A means of
documenting S. japonicum morbidity is essential to the evaluation
of disease control efforts [11].
Ultrasound is a non-invasive method that can be used to
evaluate fibrosis resulting from schistosomiasis infection. Fibrosis
along the portal vein and its branches produces a clay pipestem
pattern, as the portal tracks are lined with fibrous tissue, and is
observed following both S. mansoni and S. japonicum infection. This
periportal fibrosis can be assessed qualitatively through image
classification [12] or quantitatively by measuring the diameter of
three secondary portal branches [13]. Unique to S. japonicum
infection is parenchymal fibrosis, a network pattern that is often
described as fish scale or tortoise shell-like. Parenchymal fibrosis is
likely due to the smaller S. japonicum egg size which allows the
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portion of the liver [7]. S. japonicum adult females produce ten times
more eggs per day than S. mansoni, and the eggs often are deposited
in clusters, two additional factors that exacerbate the severity of S.
japonicum morbidity relative to other schistosome species and may
contribute to the unique fibrotic pattern [3]. Ultrasound can also
be used to assess hepatomegaly, splenomegaly and dilation of the
portal vein, all of which result from portal hypertension.
Recognizing the potential of ultrasound to be used to evaluate
the impact of disease control efforts, draft protocols for the use of
ultrasound in assessing schistosomiasis morbidity were established
for each of the three major schistosome species in 1990 [13,14].
Follow-up meetings to refine the protocols for S. haematobium and S.
mansoni were held in 1996 and 1997 [15]. Ultrasound is considered
the gold standard for schistosomiasis morbidity assessment for
these species [11]. However, due to insufficient evidence the
protocol for S. japonicum has not been revised.
To date, a comprehensive evaluation of the S. japonicum
ultrasound measures proposed in Cairo, including their relation-
ship to S. japonicum infection and the way in which they change
following treatment, is lacking. Li et al. [16,17] offer the most
complete examination of the proposed ultrasound measures to
date, tracking a highly exposed cohort over five years, but as
standard organ sizes have only recently been published [18],
assessments of liver and spleen enlargement did not account for
participant height as currently recommended [15]. Failure to
account for height-specific variation in organ sizes can lead to
underestimates of morbidity, particularly in pediatric populations
[19]. Ideally, ultrasound measures are associated with S. japonicum
infection and decline following treatment [13]. The available data
is conflicting on both criteria. Treatment led to declines in
parenchymal and periportal fibrosis in a highly exposed Chinese
cohort; however 68% of participants experienced no change in
parenchymal fibrosis over a five-year period [16,17] and other
studies have not found significant declines in periportal fibrosis
following S. japonicum treatment [20,21]. Further, a direct
relationship between infection and fibrosis or measures of portal
hypertension has not been demonstrated consistently [16,17,22].
We followed 578 individuals over five years in order to examine
the relationship between S. japonicum infection and five liver
ultrasound measurements recommended in the draft protocol as
well as two spleen ultrasound measurements included in the
standard Chinese examination. Specifically, we hypothesized that
S. japonicum infection is associated with ultrasound-detectable
measures of hepatic fibrosis and that treatment of infected
individuals leads to declines in ultrasound-detected morbidity.
Methods
Participants were drawn from a cross-sectional survey in 2000
that revealed high infection prevalence (ranging from 3% to 73%)
in 20 villages distributed in the hilly terrain of Sichuan Province in
Southwest China where irrigated agriculture for the cultivation of
rice, wheat, corn and tobacco is the primary source of S. japonicum
infection [23]. As part of the survey, all residents aged 4 to 60 years
in 20 villages Xichang County, Sichuan Province, China were
invited to be tested for S. japonicum infection and to answer a brief
questionnaire. We used a random number generator to select
approximately 30% of the population, stratified by village and
occupation, for ultrasound examination. Ten villages with high
infection prevalence in 2000 were selected to be followed
longitudinally using infection surveys and ultrasound examinations
over the next five years. Participants in our cohort included
individuals who had an ultrasound examination in 2000 and lived
in one of the ten villages followed through 2005.
Ethics statement
All participants provided oral informed consent and were
provided treatment following S. japonicum positive stool examina-
tions. As the survey procedures used in this study are the same as
those used by the Institute of Parasitic Diseases, Sichuan Center
for Disease Control and Prevention (IPD) for schistosomiasis
surveillance and given the high rates of illiteracy in the population,
oral informed consent was obtained and documented by IPD staff.
The research protocol and consent procedures were approved by
the Sichuan Institutional Review Board and the University of
California, Berkeley Committee for the Protection of Human
Subjects.
Ultrasound examination
Ultrasound examinations were conducted in fall 2000, 2002 and
2005. All examinations were conducted by one trained ultraso-
nographer (YZ) using a single portable ultrasound machine
(Hitachi EUB 405, Hitachi Corporation, Tokyo, Japan) and
3.5 MHz probe (Hitachi EUP-C314T, Hitachi Corporation,
Tokyo, Japan) with participants in the supine position at a central
location in each village. The ultrasonographer was blind to
infection status.
Liver ultrasonography was conducted according to the 1990
draft guidelines [13,14]. Liver parenchymal fibrosis was graded 1
through 3 based on observed lesions, or 0 if none were present.
Periportal fibrosis was assessed by grading the average diameter,
from outer wall to outer wall, of three peripheral branches of the
portal vein between the first and third branching point (grade 0:
,3mm; grade 1: 3 to 5 mm; grade 2: .5 to 7 mm; grade 3:
.7 mm). As done previously, grades 0 and 1 were combined for
analysis [16]. The internal diameter of the portal vein was
measured at the entry point of the portal vein into the liver. The
length of the left liver lobe was measured in a longitudinal section
along the left parasternal line, and the length of the right liver lobe
Author Summary
Schistosomiasis is a water-borne parasite that infects
approximately 200 million people worldwide. Schistosoma
japonicum, found in Asia, causes disease by releasing eggs
in the liver, leading to fibrosis, anemia, and, in children,
impaired growth. Ultrasound can assess liver pathology
from schistosomiasis; however more information is needed
to evaluate the relevance of standard ultrasound mea-
sures. We followed 578 people for up to five years, testing
for schistosomiasis infection and conducting ultrasound
examinations to assess the relationship between infection
and seven ultrasound measures and to evaluate the
impact of treatment with anti-schistosomiasis chemother-
apy (praziquantel) on morbidity. All infections were
promptly treated. Fibrosis of the liver parenchyma,
pathology unique to S. japonicum, was associated with
schistosomiasis infection, and was most advanced in
people with high worm burdens. Liver fibrosis declined
significantly following treatment, but reversal of severe
liver fibrosis was rare. Other ultrasound measures were not
consistently related to schistosomiasis infection or treat-
ment. These findings suggest parenchymal fibrosis can be
used to measure morbidity attributable to S. japonicum
and evaluate the impact of disease control efforts. Because
reversal of severe fibrosis was limited, disease control
efforts will be most effective if they can not only treat
existing infections but also prevent new infections.
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anterior axillary view according to the revised guidelines
established for S. mansoni [15].
Two measurements of the spleen that are part of the standard
Chinese examination were also included: spleen thickness,
measured from the hilum to the opposite section, and the internal
diameter of the spleen vein, measured at the entry point to the
spleen [24].
Because organ and vein sizes vary with height, left and right
liver lobe length, portal vein diameter and spleen thickness were
evaluated using height-specific standard sizes drawn from a
Chinese population where schistosomiasis is not endemic [18].
Measurements greater than two standard deviations above the
mean size for height were classified as abnormal. Height was
measured in 2002 in 440 of the 578 cohort members. The 343
adults ($18 years old in 2000) with height measurements were
assigned their 2002 height throughout the study. Children (,18
years old in 2000) were measured again in 2007 as part of a study
described elsewhere [19]. The height measurements from 2002
and 2007 from 119 children (60 with 1 height measurement, 59
with two height measurements) were used to generate an age- and
sex-dependent random intercept model in order to impute heights
during the years children weren’t measured. Height for child i at
time j was calculated using the following equation:
Hij~0:604z0:100Aij{0:003A2
ij{0:109Siz0:012AijSizfi
where Aij represents a child’s age at time j, Si represents his or her
sex (S=1 for males) and fi represents his or her random intercept.
The model was fit using xtmixed in Stata 10.1 (StataCorp, College
Station, TX, USA) and fi was predicted using empirical Bayes
[25]. As random intercept models assume parametric distribution
of residuals, first and second order residuals were examined and
were normally distributed. The selected model was superior to a
model that did not include a random intercept (likelihood ratio
test, x
2=38.20, 1 d.f., p,0.001). Organ and vessel measures
could not be height adjusted for the 86 adults and 26 children
without height measurements. Participants with any versus no
height data did not differ significantly by any of the predictors
examined in the analyses including sex, mean age or infection
status. No height standardized values were available for spleen
vein diameter, so it was evaluated by the standard threshold used
in China: .8 mm [24].
Infection and treatment
Participants were tested for infection with S. japonicum in the fall
of 2000 and 2002 using the miracidial hatch test [26] and the
Kato-Katz thick smear procedure [27]. For each hatch test, a stool
sample weighing at least 30 g was suspended in aqueous solution,
filtered using copper mesh to remove large particles (40–60 mesh)
followed by nylon gauze (260 mesh) to concentrate schistosome
eggs. This sediment was re-suspended with distilled water in a
250 ml Erlenmeyer flask. Flasks were examined for miracidia 30–
60 minutes, 4 hours and 8 hours after suspension if temperatures
were above 30 degrees Celsius, or at 6, 12 and 18 hours at lower
ambient temperatures. In 2000, three miracidial hatch tests were
conducted per person using stool samples from three distinct days.
In 2002, due to logistical constraints, one miracidial hatch test was
conducted per person; however the Kato-Katz protocol was
identical both years. The Kato-Katz procedure involved the
preparation of three 41.5 mg slides from one homogenized stool
sample in 2000 and 2002. Infection intensity, in eggs per gram of
stool (EPG), was calculated as the total number of S. japonicum eggs
present on the slides divided by the total sample weight.
Participants were classified as infected if at least one test was
positive. Everyone testing positive for S. japonicum was provided
praziquantel treatment by the county Anti-Schistosomiasis Con-
trol Station. In addition, praziquantel was administered to all
residents in the study villages in 2003, as part of a nation-wide
effort to control infectious diseases following the outbreak of severe
acute respiratory syndrome.
Participant age, sex, occupation and highest level of schooling
were obtained by interview in fall 2000.
Statistical analysis
In order to assess whether the participants in the ultrasound
cohort were representative of the village populations from which
they were selected, cohort participants were compared to
individuals who participated only in the cross-sectional demo-
graphic and infection surveys in terms of age, sex, occupation,
educational attainment and 2000 S. japonicum infection status.
Similarly, cohort members with complete vs. incomplete follow-up
were compared in terms of age, sex, baseline morbidity and
infection in order to assess non-differential loss to follow-up. In
both cases, comparisons were conducted using the x
2 and t-test.
Analyses that included multiple observations from individuals
accounted for within subject correlation of outcomes. Liver
parenchymal fibrosis grade, an ordinal measure, was examined
using ordinal logistic regression, a population averaged model
using a sandwich type estimator for inference accounting for
within-subject residual correlation [28]. Because ordinal logistic
regression assumes the effect of a predictor on an outcome is
constant for each stepwise increase in the outcome, the Brant test
[29] was used to check that this parallel regression assumption was
not violated. For all other liver and spleen measures and for
predictors of S. japonicum infection status, generalized estimating
equation (GEE) logistic regression with exchangeable correlation
was conducted [30]. The Huber/White/sandwich estimator of
variance was used which is robust to misspecification of the
outcome distribution [31,32].
Table 1. Characteristics of the 578 participants in the
ultrasound cohort in 2000.
No. (%)
Sex
Female 295 (51)
Male 279 (49)
Age
,18 145 (25)
18–29 141 (25)
30–39 130 (23)
40–49 95 (17)
50+ 63 (11)
Occupation
1
Not farmer 37 (9)
Farmer 392 (91)
Education
1
Elementary school or less 253 (59)
Some middle school or higher 175 (41)
1Includes adults (.18 years) only.
doi:10.1371/journal.pntd.0000685.t001
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detected abnormalities was first assessed by examining the impact
of current infection status and, separately, infection intensity, on
current ultrasound measures. Because infection intensity was
highly right skewed, it was categorized into approximate quartiles
among those who were infected. In order to examine the role of
past infection on current morbidity, we also examined the
relationship between infection status and intensity two to three
years prior to the ultrasound examination and ultrasound-detected
abnormalities (for example: 2000 infection status as a predictor of
ultrasound-detected morbidity in 2002, and 2002 infection status
as a predictor of ultrasound-detected morbidity in 2005). We
hypothesized that age, sex and year of examination could modify
the effect of infection on morbidity, so each model was run
including all possible first-order interaction terms. The Wald test
was used to test for significant interactions and if present, terms
were removed from the model step-wise until only interaction
terms significant at p-values ,0.05 remained. In the absence of
effect modification, these same variables could confound the
relationship between infection and ultrasound-detected morbidity.
While occupation, village and educational status were considered
potential predictors of S. japonicum infection, they are unlikely to
effect ultrasound morbidity independent of infection status. As
they do not fit the definition of confounders [33], they were not
controlled for in models examining the relationship between
infection and ultrasound-detected abnormalities. The change in
ultrasound-detected abnormalities over time was examined
adjusting for age and sex.
We modeled age as a categorical variable when examining the
relationship between age and ultrasound-detected morbidity to
allow a non-linear relationship. Because liver abnormalities
increase with age, age was treated as a continuous variable when
included as a confounder in models testing the relationship
between infection and morbidity, or changes in morbidity over
Table 2. The distribution of S. japonicum infection by age, sex, occupation, educational attainment, year and village.
2000 2002
n Infected (%) n Infected (%) OR (95% CI)
1
Year
Year 2000 564 265 (47) 1.00
Year 2002 504 161 (32) 0.53 (0.42–0.66)
Sex
Female 288 147 (51) 260 78 (30) 1.00
Male 276 118 (43) 244 83 (34) 0.89 (0.69–1.16)
Age
,18 138 63 (46) 101 29 (29) 1.00
18–29 140 65 (46) 98 30 (31) 1.06 (0.72–1.56)
30–39 129 70 (54) 150 59 (39) 1.33 (0.93–1.92)
40–49 95 49 (52) 75 23 (31) 1.16 (0.78–1.73)
50+ 62 18 (29) 80 20 (25) 0.58 (0.36–0.95)
p-value, test for trend
2 0.209
Occupation
3
Not farmer 37 13 (35) 35 9 (26) 1.00
Farmer 389 189 (49) 368 123 (33) 1.59 (0.84–3.01)
Education
3
Elementary school or less 252 134 (53) 240 81 (34) 1.00
Some middle school or higher 173 68 (39) 162 51 (31) 0.70 (0.51–0.96)
Village
Xinming3 63 32 (51) 54 18 (33) 1.00
Tuanjie2 58 6 (10) 56 8 (14) 0.19 (0.09–0.39)
Jiaojia4 59 13 (22) 54 7 (13) 0.29 (0.15–0.54)
Hexing1 61 19 (31) 59 8 (14) 0.39 (0.22–0.71)
Minhe1 67 29 (43) 55 23 (42) 0.99 (0.57–1.72)
Minhe3 61 35 (57) 56 20 (36) 1.18 (0.71–1.99)
Xinlong7 45 27 (60) 38 16 (42) 1.45 (0.80–2.62)
Jianxing6 60 41 (68) 48 21 (44) 1.81 (1.09–3.03)
Xinming7 45 31 (69) 42 19 (45) 1.82 (1.06–3.11)
Shian5 45 32 (71) 42 21 (50) 2.08 (1.14–3.81)
1Odds ratios account for multiple observations from the same individual using generalized estimating equations with exchangeable correlation and robust inference.
2Test for trend was calculated by treating age categories as ordinal.
3Analysis included adults ($18 years) only.
doi:10.1371/journal.pntd.0000685.t002
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grades 0 and 1 were combined and no grade 3 fibrosis was
detected. Tests for trend were calculated by treating categorical
variables as ordinal. All results were assessed for statistical
significance setting a=0.05. Statistical analyses were conducted
using Stata 10.1 (StataCorp, College Station, TX, USA).
Results
In 2000, 578 people from ten villages were examined using
ultrasound. The mean age of participants was 29.8 years (range 4–
61 years). Half (51%) were female (Table 1). Most adults ($18
years) were farmers (91%) and had no formal schooling beyond
elementary school (59%). Participants were similar in terms of
occupation, educational attainment and 2000 infection status to
the 1,333 residents in these villages who participated in infection
and demographic surveys only, although cohort members were
slightly older than the rest of the population (mean age 29.8 vs.
28.2, p=0.037).
We conducted ultrasound examinations with 444 people in
2002 and 321 people in 2005. The 320 people with complete
ultrasound follow-up were no more likely to be infected with S.
japonicum at enrollment than those who missed at least one follow-
up examination, but they were older (mean age 33.0 vs. 25.6,
p,0.001) and more likely to have at least one liver abnormality in
2000 (57% vs. 37%, p,0.001).
Nearly half (47%) of participants tested positive for S. japonicum
in 2000. Mean infection intensity was 53.4 EPG. In 2002, infection
prevalence declined to 32% and intensity to 9.4 EPG. As shown in
Table 2, adults aged 50 and older were less likely to be infected
than younger participants. Neither sex nor occupation was
associated with infection prevalence, but among adults, higher
educational attainment was protective. Infection prevalence in
2002 was significantly higher among those who were infected vs.
uninfected in 2000 despite the distribution of treatment to
everyone who tested positive (41% vs. 23%, p,0.001). Infection
prevalence varied significantly by village.
Table 3 describes the prevalence of liver parenchymal fibrosis,
periportal fibrosis and abnormal liver and spleen measurements
from 2000 to 2005. Following the initiation of schistosomiasis
testing and treatment of all infections in 2000, parenchymal
fibrosis, periportal fibrosis and right liver lobe enlargement
decreased significantly through 2005, controlling for age and sex
(Table 4). Decreases in spleen enlargement were also observed,
although the trend was of marginal significance (p=0.091).
Liver abnormalities increased significantly with age, most
notably for parenchymal fibrosis (Table 4). Spleen enlargement
was not associated with age. Individuals aged 18 to 29 years had
the highest odds of spleen vein dilation. The relationship between
liver abnormalities and sex varied: men were more likely to have
periportal fibrosis and enlarged right liver lobes; women were
more likely to have enlarged left liver lobes.
Schistosomiasis infection at the time of ultrasound was
associated with an increase in liver parenchymal fibrosis grade
(OR 1.40, 95% CI: 1.03–1.90) adjusting for age, sex and year of
ultrasound (Table 5). Infection intensity at the time of ultrasound
was also associated with an increase in liver parenchymal fibrosis
grade (test for trend: p=0.002). Individuals with greater than 50
EPG had 2.10 times greater odds of more advanced fibrosis than
those not excreting eggs (95% CI: 1.33–3.32).
Schistosomiasis infection two to three years prior to ultrasound
was associated with an increase in liver parenchymal fibrosis
grade, and the association was stronger than that of current
infection (OR 1.84, 95% CI: 1.30–2.60). Prior infection intensity
was also associated with liver parenchymal fibrosis (test for trend,
p,0.001). Individuals with greater than 50 EPG two to three years
prior to the ultrasound examination had 2.84 times greater odds of
advanced fibrosis than those not excreting eggs two to three years
prior to ultrasound (95% CI: 1.71–4.73).
The other hepatosplenic ultrasound measures were not
associated with current infection status or intensity. Several
measures were associated with prior infection, although the
relationships were not as consistent as those observed for
periportal fibrosis. Prior infection appeared to elevate the
probability of left liver lobe enlargement (OR 1.45, 95% CI:
0.97–2.17). Prior infection intensity but not prior infection status,
was associated with increased odds of portal vein dilation (test for
trend, p=0.051). The impact of prior infection status on right liver
lobe enlargement varied by the year of examination and the sex of
the participant. Prior infection was associated with increased odds
of right liver lobe enlargement among males examined in 2005
(OR 3.95, 95% CI: 1.82–8.57) and decreased odds of right liver
lobe enlargement among females examined in 2002 (OR 0.33,
95% CI: 0.13–0.86). Prior infection intensity was not associated
with right or left liver lobe enlargement. Due to the limited
number of individuals with periportal fibrosis, models were unable
Table 3. Prevalence of abnormal liver and spleen
measurements from 2000 to 2005.
2000 2002 2005
No. (%) No. (%) No. (%)
Parenchymal fibrosis
Grade 0 388 (67) 297 (67) 219 (68)
Grade 1 83 (14) 50 (11) 35 (11)
Grade 2 92 (16) 88 (20) 58 (18)
Grade 3 15 (3) 9 (2) 9 (3)
Periportal fibrosis
Grade 0 (av. diameter ,3 mm) 22 (4) 24 (5) 19 (6)
Grade 1 (av. diameter 3 to 5 mm) 535 (93) 401 (90) 299 (93)
Grade 2 (av. diameter 5.1 to 7 mm) 21 (4) 19 (4) 3 (1)
Grade 3 (av. diameter .7 mm) 0 (0) 0 (0) 0 (0)
Left liver lobe
1
Normal 389 (84) 373 (85) 250 (79)
Enlarged 73 (16) 67 (15) 67 (21)
Right liver lobe
1
Normal 351 (76) 402 (91) 277 (87)
Enlarged 111 (24) 38 (9) 40 (13)
Portal vein
1
Normal 417 (90) 383 (87) 274 (86)
Dilated 45 (10) 57 (13) 43 (14)
Spleen (thickness)
1
Normal 442 (96) 425 (97) 310 (98)
Enlarged 18 (4) 14 (3) 6 (2)
Spleen vein
2
Normal 549 (95) 406 (92) 313 (98)
Dilated 28 (5) 37 (8) 7 (2)
1Enlargement of the left liver lobe, right liver lobe and spleen, and portal vein
dilation were classified based on height-specific normal values [18].
2The spleen vein was classified as dilated if the diameter exceeded 8 mm.
doi:10.1371/journal.pntd.0000685.t003
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measure Spleen enlargement and spleen vein dilation were not
associated with current or prior infection.
Most people with liver and spleen enlargement, portal vein
dilation, periportal fibrosis or spleen vein dilation in 2000 had
normal pathology by 2002 (Table 6). However, this was not the
case for parenchymal fibrosis: 67% of people with grade 2 fibrosis
and 100% with grade 3 fibrosis in 2000 remained at or above
grade 2 throughout the five-year follow-up.
Discussion
We found evidence of a direct, exposure-response relationship
between S. japonicum infection and parenchymal fibrosis. While
there has been suggestive evidence of an association between
infection and parenchymal fibrosis, including an association
between progression of parenchymal fibrosis and current infection
[16], this is the first study to show the risk of parenchymal fibrosis
is higher in people who are infected vs. uninfected, and highest in
individuals with the greatest infection intensities. Parenchymal
fibrosis declined significantly following treatment however,
improvements were limited among individuals with advanced
fibrosis: 72% of people with severe fibrosis at enrollment (grades 2
or 3) had not resolved below grade 2 by the end of the five-year
study. This suggests parenchymal fibrosis is an appropriate
measure of S. japonicum morbidity and can document improve-
ments in morbidity following treatment, although little improve-
ment may be observed among those with advanced fibrosis.
In contrast, the remaining measures were less consistently
associated with S. japonicum infection and are of questionable
epidemiological use in regions with similar infection levels.
Periportal fibrosis was rare in this population and could not be
associated with S. japonicum infection, although it did decline
significantly following the initiation of targeted treatment. Others
have used image-based classification to assess periportal fibrosis
[34,35], which has been shown to have better reproducibility for S.
mansoni-related fibrosis, perhaps because it does not require the
ultrasonographer to measure narrow vessel widths [36]. Our
measures of periportal fibrosis were not height adjusted, as
Chinese standards for the diameter of portal vein branches as
measured here have not been published. The lack of height
adjustment may have led to underestimates of the prevalence of
periportal fibrosis and may explain the higher prevalence of
periportal fibrosis in men, however higher prevalence of fibrosis
has also been observed in males using image-based classification
[35].
The remaining three hepatic measures, left and right liver lobe
enlargement and portal vein dilation, were associated with S.
japonicum infection or declined following chemotherapy. However,
the relationships between S. japonicum infection and these
morbidity measures were less consistent than those observed with
parenchymal fibrosis and several associations were of marginal
statistical significance. The spleen measures were neither associ-
ated with infection nor did they decline with treatment. All five
measures require the ultrasonographer to measure organ or vessel
sizes and participant’s height. Like the measures of periportal
fibrosis used here, these methods present opportunities for
measurement error which may bias estimates of exposure-disease
relationships toward the null, producing attenuation and exacer-
bating non-linearity [37]. The reproducibility of some of these
Table 4. The relationship between ultrasound-detected abnormalities and age, sex and year.
Parenchymal
fibrosis
Periportal
fibrosis
1
Left liver lobe
enlargement
2
Right liver lobe
enlargement
2
Portal vein
dilation
2
Spleen
enlargement
2
Spleen vein
dilation
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Sex
Female 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Male 1.18 (0.85–1.64) 4.35 (2.05–9.23) 0.41 (0.28–0.60) 1.88 (1.29–2.73) 1.28 (0.87–1.89) 0.89 (0.43–1.83) 1.22 (0.74–2.01)
Age
3
,18 1.00 1.00 1.00 1.00 1.00 1.00 1.00
18–29 10.44 (5.11–21.33) 9.36 (1.14–76.56) 2.91 (1.35–6.29) 2.40 (1.25–4.61) 2.00 (0.93–4.33) 3.40 (1.02–11.34) 3.18 (1.34–7.58)
30–39 11.76 (5.96–23.18) 9.79 (1.31–73.01) 4.00 (2.03–7.89) 2.91 (1.61–5.28) 3.19 (1.58–6.44) 2.09 (0.63–6.88) 2.60 (1.11–6.12)
40–49 30.76 (15.21–62.20) 10.95 (1.41–85.30) 4.56 (2.25–9.23) 3.13 (1.65–5.95) 2.82 (1.35–5.91) 1.74 (0.45–6.78) 1.35 (0.46–3.94)
50+ 35.89 (17.45–73.80) 8.47 (1.07–67.07) 6.21 (3.05–12.63) 3.26 (1.66–6.41) 3.98 (1.97–8.06) 1.82 (0.47–6.98) 2.32 (0.93–5.79)
trend
4 ,0.001 0.025 ,0.001 ,0.001 ,0.001 0.894 0.548
Year
5
2000 1.00 1.00 1.00 1.00 1.00 1.00 1.00
2002 0.82 (0.68–0.98) 1.07 (0.59–1.96) 0.86 (0.62–1.19) 0.26 (0.18–0.37) 1.28 (0.87–1.88) 0.79 (0.42–1.49) 1.79 (1.09–2.93)
2005 0.57 (0.44–0.73) 0.20 (0.06–0.63) 1.11 (0.77–1.60) 0.35 (0.24–0.52) 1.20 (0.78–1.84) 0.43 (0.16–1.20) 0.41 (0.17–0.95)
trend
4 ,0.001 0.002 0.634 ,0.001 0.362 0.091 0.119
1Periportal fibrosis was treated as a binary variable, comparing grade 2 to grades 0 and 1.
2Enlargement of the left liver lobe, right liver lobe, spleen, and portal vein dilation were classified based on height-specific normal values.
3There were no children (,18) with grade 3 parenchymal fibrosis, leading to a violation of the parallel regression assumption for ordinal logistic regression. For this
analysis, grade 3 was grouped with grade 2 in order to avoid a model violation.
4The test for trend was calculated by treating categories as ordinal.
5Analysis adjusted for age and sex.
All odds ratios account for multiple observations from the same individual. Ordinal logistic regression with a sandwich type estimator was used for parenchymal fibrosis.
Generalized estimating equations logistic regression with exchangeable correlation was used for all other measures.
doi:10.1371/journal.pntd.0000685.t004
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further efforts to evaluate the accuracy of organ and vein size
measurements are needed [19].
Overall, the prevalence of morbidity in this cohort was lower
than has been observed elsewhere in China as was infection
intensity [16,17,34,38]. Measures of liver and spleen enlargement,
portal vein dilation and spleen vein dilation were less informative
than measures of parenchymal fibrosis but may be appropriate in
areas where infection intensity and associated morbidities are
higher. Declines in hepatomegaly and splenomegaly have been
Table 5. The impact S. japonicum infection on ultrasound-detected liver abnormalities.
Parenchymal fibrosis Left liver lobe enlargement Portal vein dilation
Adjusted
1 Unadjusted Adjusted
1 Unadjusted Adjusted
1 Unadjusted
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
I. Current infection (n=977)
2
Uninfected 1.00 1.00 1.00 1.00 1.00 1.00
Infected 1.40 (1.03–1.90) 1.21 (0.91–1.61) 1.05 (0.73–1.51) 1.00 (0.72–1.40) 0.86 (0.55–1.35) 0.80 (0.51–1.25)
II. Current inf. intensity
(n=976)
2
0 EPG 1.00 1.00 1.00 1.00 1.00 1.00
1–10 EPG 1.50 (0.99–2.27) 1.36 (0.91–2.05) 1.04 (0.55–1.97) 1.02 (0.55–1.91) 1.10 (0.56–2.15) 1.05 (0.54–2.04)
11–50 EPG 1.30 (0.82–2.08) 1.22 (0.81–1.85) 0.94 (0.50–1.75) 0.93 (0.51–1.69) 0.94 (0.45–1.98) 0.86 (0.40–1.81)
.50 EPG 2.10 (1.33–3.32) 1.46 (0.95–2.25) 1.71 (0.94–3.12) 1.47 (0.84–2.55) 0.82 (0.35–1.93) 0.66 (0.28–1.57)
p-value, test for trend
3 0.002 0.052 0.185 0.301 0.691 0.353
III. Prior infection (n=739)
4
Uninfected 1.00 1.00 1.00 1.00 1.00 1.00
Infected 1.84 (1.30–2.60) 1.48 (1.06–2.05) 1.45 (0.97–2.17) 1.18 (0.81–1.72) 1.09 (0.71–1.68) 1.00 (0.65–1.52)
IV. Prior inf. intensity
(n=739)
4
0 EPG 1.00 1.00 1.00 1.00 1.00 1.00
1–10 EPG 1.71 (1.04–2.79) 1.42 (0.90–2.24) 1.21 (0.68–2.15) 1.07 (0.62–1.86) 0.50 (0.20–1.29) 0.47 (0.19–1.17)
11–50 EPG 2.07 (1.21–3.57) 1.79 (1.08–2.97) 1.39 (0.79–2.42) 1.17 (0.67–2.04) 1.37 (0.71–2.66) 1.25 (0.66–2.38)
.50 EPG 2.84 (1.71–4.73) 1.81 (1.14–2.89) 1.12 (0.57–2.20) 0.79 (0.41–1.52) 2.02 (1.05–3.89) 1.55 (0.84–2.85)
p-value, test for trend
3 ,0.001 0.002 0.440 0.712 0.051 0.194
1Adjusted models controlled for age, sex and year of ultrasound.
2Current infection status and intensity was assessed at the time of an ultrasound examination.
3The test for trend was calculated by treating infection intensity categories as ordinal.
4Prior infection status and intensity was assessed two to three years before an ultrasound examination (in 2000 for the 2002 ultrasound examination, 2002 for the 2005
ultrasound examination).
All odds ratios account for multiple observations from the same individual. Ordinal logistic regression with a sandwich type estimator was used for parenchymal fibrosis.
Generalized estimating equations logistic regression with exchangeable correlation was used for all other measures.
For each liver abnormality, four measures of infection are examined: current infection status, current infection intensity, prior infection status and prior infection
intensity.
doi:10.1371/journal.pntd.0000685.t005
Table 6. The reversal of ultrasound-detected liver and spleen abnormalities among individuals with abnormal measures in 2000.
No. in 2000
1 Reversed in 2002 Reversed in 2005 Never reversed
No. (%) No. (%) No. (%)
Parenchymal fibrosis (grade 2 or 3)
2 71 11 (15) 17 (24) 51 (72)
Periportal fibrosis (grade 2) 17 14 (82) 16 (94) 0 (0)
Left liver lobe enlarged 58 35 (60) 35 (60) 13 (22)
Right liver lobe enlarged 85 65 (76) 63 (74) 10 (12)
Portal vein dilated 33 22 (67) 24 (73) 5 (15)
Spleen enlarged 16 13 (81) 16 (100) 0 (0)
Spleen vein dilated 16 12 (75) 15 (94) 0 (0)
1Includes only individuals with complete follow-up data.
2Regression to parenchymal fibrosis grade 0 or 1 was classified as reversal.
doi:10.1371/journal.pntd.0000685.t006
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worm burdens [16,17]. The strong associations between age and
all liver measures highlight the importance of considering age as a
potential confounder when examining the relationship between S.
japonicum infection and morbidity and declines in morbidity over
time. For example, the unadjusted prevalence of parenchymal
fibrosis did not change over time, however as loss to follow-up was
highest in younger populations which were least likely to have
fibrosis, the age and sex adjusted prevalence did decline.
Our findings shed light on the development of hepatic fibrosis
following S. japonicum infection. The lack of reversal of grade 3
parenchymal fibrosis to grade 1 or normal and the association
between past infection and current fibrosis suggest severe fibrosis
may persist or even progress following treatment. Prior studies
have also found minimal reversal of severe fibrosis following
treatment [16,39] and hepatic fibrosis has been documented in
people living in areas where the parasite, and therefore exposure,
was eliminated 20 years previously [40]. While treatment with
praziquantel can reduce infection prevalence, intensity and
fibrosis, this analysis provides further evidence that severe hepatic
fibrosis may be unlikely to reverse quickly. Minimal declines in
severe hepatic fibrosis associated with S. mansoni infection have also
been detected [41] but other studies have noted complete reversal
of severe morbidity [42].
Further, parenchymal fibrosis was associated with current
infection status and intensity but more strongly associated with
infection status and intensity two to three years prior to
ultrasound, despite timely treatment of infections. The surprising
association between past infection and fibrosis raises questions
about the progression of fibrosis following infection and treatment.
Praziquantel kills the adult worm but schistosome eggs can remain
trapped in host tissues decades after exposure [43]. While
schistosome eggs are thought to disintegrate within weeks of
granuloma formation [7], it is possible, due to an inflammatory
cascade, fibrogenesis continues over a longer time period.
Collagen deposition has been shown to occur following treatment
with praziquantel in S. japonicum infected mice, suggesting fibrosis
may continue despite removal of adult worms [44]. In humans,
progression of fibrosis has been observed following treatment and
was not explained by reinfection [21,45]. Alternatively, it is
possible that the relationship between past infection and fibrosis is
due to reinfection. Past infection predicted subsequent infection.
However, if reinfection rather than past infection determined
fibrosis, one would expect stronger relationships between current
infection and fibrosis than between past infection and fibrosis,
which was not observed. It is also possible that some individuals
who were treated were not cured. A single dose of praziquantel
cures 90% of S. japonicum infections [46], suggesting 10% of those
treated may continue to harbor adult worms and face continued
egg production. In our work in this region, we have also found
individuals who decline to take praziquantel even after a positive
infection test. Non-compliance and treatment failure are realities
of any chemotherapy-based control program, however the marked
declines in infection prevalence, intensity and morbidity suggest
the number of individuals who were not cured was limited.
This study examined one of the largest populations to be
followed over five years in order to assess ultrasound-detectable
morbidity and S. japonicum infection. Participants were randomly
sampled from a comprehensive cross-sectional survey in order to
minimize selection bias. Loss to follow-up was greater among those
without ultrasound-detectable morbidity, which suggests the
prevalence of morbidity in 2002 and 2005 may be overestimated,
and therefore the true declines in morbidity over time may be
greater than observed. Retention was independent of infection
status, minimizing bias in estimates of the impact of infection on
pathology. No information was available on alcohol consumption
or infection with hepatitis B virus (HBV), two factors that can
induce liver pathology and may exacerbate schistosomiasis
morbidity. The parenchymal network pattern due to S. japonicum
is distinct from the lesions produced by HBV, as HBV produces a
finer, meshwork texture [47], suggesting the observed prevalence
of parenchymal fibrosis is specific to schistosomiasis. While HBV
has been shown to hinder regression of periportal fibrosis following
treatment of S. mansoni infections [41], the extent to which HBV
exacerbates morbidity due to S. japonicum remains unclear and
warrants further study. Reductions in parenchymal fibrosis may be
impaired by alcohol consumption, which in our study areas is
confined almost exclusively to males [17]. Unless alcohol
consumption or HBV impacts a person’s probability of infection,
they are unlikely to confound the relationships between infection
and ultrasound-detected morbidity.
Community-wide testing and treatment of all infections with
praziquantel yielded marked declines in infection prevalence and
intensity. However, reinfection was high: 32% of people were
infected two years after the first round of targeted treatment. High
rates of infection following treatment are not uncommon and
underscore the challenges of sustainably reducing human
schistosomiasis [48]. Adults aged 50 and over were less likely to
be infected than younger populations, possibly corresponding to a
decline in water contact later in life or acquired immunity [49].
In summary, we present evidence that ultrasound-detectable
liver fibrosis is associated with S. japonicum infection status and
intensity, controlling for age, sex and year of ultrasound
examination, and this measure can be used to monitor S. japonicum
induced morbidity. Other ultrasound measures including hepato-
megaly and splenomegaly were less clearly associated with
infection. Our findings also suggest that some morbidity may not
reverse within five years of treatment and may even progress
despite treatment. Praziquantel has yielded remarkable declines in
schistosomiasis morbidity in China and throughout the globe but
reinfection following treatment is common as observed in this
study population. S. japonicum infection, particularly high egg loads,
may lead to fibrosis that is not rapidly reversed by treatment,
underscoring the importance of measures to prevent new
infections as well as treating current disease.
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